Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Wong, C.H.; Dumas, D.P.; Ichikawa, Y.; Koseki, K.; Danishefsky, S.J.; Weston, B.W.; Lowe, J.B.
    Specificity, inhibition, and synthetic utility of a recombinant human alpha-1,3-fucosyltransferase (1992), J. Am. Chem. Soc., 114, 7321-7322.
No PubMed abstract available

Inhibitors

EC Number Inhibitors Comment Organism Structure
2.4.1.65 2'-fucosyllactose
-
 Homo sapiens
2.4.1.65 Galbeta(1,3)GalNAc
-
 Homo sapiens
2.4.1.65 Galbeta(1,4)(3-deoxy)GlcNAcbetaOallyl IC50: 710 mM Homo sapiens
2.4.1.65 Galbeta(1,4)deoxynojirimycin IC50: 8 mM Homo sapiens
2.4.1.65 GDP 0.05 mM Homo sapiens
2.4.1.65 GDP-Man IC50: 2 mM Homo sapiens

KM Value [mM]

EC Number KM Value [mM] KM Value Maximum [mM] Substrate Comment Organism Structure
2.4.1.65 0.012
-
 Galbeta(1,4)(5-thioGlc)
-
 Homo sapiens
2.4.1.65 0.016
-
 Galbeta(1,4)GlcNAcbetaOallyl
-
 Homo sapiens
2.4.1.65 0.034
-
 Galbeta(1,4)Glucal
-
 Homo sapiens
2.4.1.65 0.035
-
 Galbeta(1,4)GlcNAc
-
 Homo sapiens
2.4.1.65 0.064
-
 NeuAcalpha(2,3)Galbeta(1,4)Glucal
-
 Homo sapiens
2.4.1.65 0.07
-
 NeuAcalpha(2,6)Galbeta(1,4)GlcNAc
-
 Homo sapiens
2.4.1.65 0.1
-
 NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
-
 Homo sapiens
2.4.1.65 0.28
-
 NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
-
 Homo sapiens
2.4.1.65 0.4
-
 Galbeta(1,4)GlcNAcbeta(1,2)Man
-
 Homo sapiens
2.4.1.65 0.5
-
 Galbeta(1,4)Glc
-
 Homo sapiens
2.4.1.65 0.6
-
 Galbeta(1,3)GlcNAc
-
 Homo sapiens
2.4.1.65 0.8
-
 Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
 Homo sapiens

Organism

EC Number Organism UniProt Comment Textmining
2.4.1.65 Homo sapiens
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
2.4.1.65 milk
-
 Homo sapiens
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.4.1.65 GDP-beta-L-fucose + NeuAcalpha(2,6)Galbeta(1,4)GlcNAc
-
 Homo sapiens ?
-
 ?
2.4.1.65 GDP-L-fucose + 2'-fucosyllactose
-
 Homo sapiens GDP + ?
-
 ?
2.4.1.65 GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
 Homo sapiens GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
 ?
2.4.1.65 GDP-L-fucose + Galbeta(1,3)GlcNAc 130% of the activity with Galbeta(1,4)GlcNAc Homo sapiens GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
 ?
2.4.1.65 GDP-L-fucose + Galbeta(1,4)-(5-thioGlc) 51% of the activity with Galbeta(1,4)GlcNAc Homo sapiens GDP + ?
-
 ?
2.4.1.65 GDP-L-fucose + Galbeta(1,4)Glc
-
 Homo sapiens GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
 ?
2.4.1.65 GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
-
 Homo sapiens GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
-
 ?
2.4.1.65 GDP-L-fucose + Galbeta(1,4)GlcNAcbetaOallyl 64% of the activity with Galbeta(1,4)GlcNAc Homo sapiens GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl
-
 ?
2.4.1.65 GDP-L-fucose + Galbeta(1,4)Glucal 10% of the activity with Galbeta(1,4)GlcNAc Homo sapiens GDP + Galbeta(1,4)(Fucalpha(1,3))Glucal
-
 ?
2.4.1.65 GDP-L-fucose + NeuAc(2,3)Galbeta(1,4)Glucal 330% of the activity with Galbeta(1,4)GlcNAc Homo sapiens GDP + NeuAc(2,3)Galbeta(1,4)(Fucalpha(1,3))Glucal
-
 ?
2.4.1.65 GDP-L-fucose + NeuAc(2,6)Galbeta(1,4)GlcNAc 13% of the activity with Galbeta(1,4)GlcNAc Homo sapiens GDP + NeuAc(2,6)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
 ?
2.4.1.65 GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAc 620% of the activity with Galbeta(1,4)GlcNAc Homo sapiens GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
 ?
2.4.1.65 GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbetaOallyl 380% of the activity with Galbeta(1,4)GlcNAc Homo sapiens GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl
-
 ?

IC50 Value

EC Number IC50 Value IC50 Value Maximum Comment Organism Inhibitor Structure
2.4.1.65 2
-
 IC50: 2 mM Homo sapiens GDP-Man
2.4.1.65 8
-
 IC50: 8 mM Homo sapiens Galbeta(1,4)deoxynojirimycin
2.4.1.65 710
-
 IC50: 710 mM Homo sapiens Galbeta(1,4)(3-deoxy)GlcNAcbetaOallyl